Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

An unprecedented number of human infections with avian influenza A(H7N9) in the fifth epidemic wave during the winter of 2016–2017 in China and their antigenic divergence from the viruses that emerged in 2013 prompted development of updated vaccines for pandemic preparedness. We report on the findin...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2021-03, Vol.6 (1), p.41-41, Article 41
Main Authors: Oshansky, Christine M., King, James, Lu, Di, Zhou, James, Pavetto, Corrina, Horwith, Gary, Biscardi, Karen, Nguyen, Bai, Treanor, John J., Chen, Li-Mei, Jepson, Brett, Bright, Rick A., Johnson, Robert A., Cioce, Vittoria, Donis, Ruben O.
Format: Article
Language:English
Subjects:
631/250/255
631/250/255/1578
631/250/590/2291
631/250/590/2294
692/699/255/1578
Adjuvants
Adults
Antibodies
Biomedical and Life Sciences
Biomedicine
Epidemics
Immune system
Immunogenicity
Infectious Diseases
Influenza
Medical Microbiology
Pandemics
Public Health
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An unprecedented number of human infections with avian influenza A(H7N9) in the fifth epidemic wave during the winter of 2016–2017 in China and their antigenic divergence from the viruses that emerged in 2013 prompted development of updated vaccines for pandemic preparedness. We report on the findings of a clinical study in healthy adults designed to evaluate the safety and immunogenicity of three dose levels of recombinant influenza vaccine derived from highly pathogenic A/Guangdong/17SF003/2016 (H7N9) virus adjuvanted with AS03 or MF59 oil-in water emulsions. Most of the six study groups meet the FDA CBER-specified vaccine licensure criterion of 70% seroprotection rate (SPR) for hemagglutination inhibition antibodies to the homologous virus. A substantial proportion of subjects show high cross-reactivity to antigenically distinct heterologous A(H7N9) viruses from the first epidemic wave of 2013. These results provide critical information to develop a pandemic response strategy and support regulatory requirements for vaccination under Emergency Use Authorization.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-021-00287-7